Emerging strategies for treating brain metastases from breast cancer.

[1]  L. Cantley,et al.  Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. , 2015, Cancer research.

[2]  G. B. Gelaleti,et al.  Abstract A03: Effectiveness of melatonin on the epithelial mesenchymal transition after induction with transforming growth factor beta (TGF-β) , 2015 .

[3]  I. Fidler,et al.  Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. , 2014, Neuro-oncology.

[4]  R. Jain,et al.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[5]  F. Montemurro,et al.  Metastatic breast cancer subtypes and central nervous system metastases. , 2014, Breast.

[6]  V. Zagonel,et al.  Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. , 2014, Cancer treatment reviews.

[7]  W. Hahn,et al.  Analysis of tumor- and stroma-supplied proteolytic networks reveals a brain metastasis-promoting role for cathepsin S , 2014, Nature Cell Biology.

[8]  K. Blennow,et al.  Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. , 2014, International journal of radiation oncology, biology, physics.

[9]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[10]  M. Kris,et al.  Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis , 2014, Cell.

[11]  H. Nakshatri,et al.  Angiopoietin‐2 mediates blood–brain barrier impairment and colonization of triple‐negative breast cancer cells in brain , 2014, The Journal of pathology.

[12]  R. Kurzrock,et al.  Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Campone,et al.  Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  V. Manda,et al.  P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model , 2013, Front. Pharmacol..

[15]  Yasuyoshi Watanabe,et al.  64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer , 2013, The Journal of Nuclear Medicine.

[16]  C. Miller,et al.  αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain , 2013, Clinical Cancer Research.

[17]  M. Hung,et al.  Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis , 2013, PloS one.

[18]  W. Geldenhuys,et al.  Paclitaxel–Hyaluronic NanoConjugates Prolong Overall Survival in a Preclinical Brain Metastases of Breast Cancer Model , 2013, Molecular Cancer Therapeutics.

[19]  K. Ji,et al.  Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis , 2013, Oncogene.

[20]  T. Ishikawa,et al.  Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model , 2013, Journal of Cancer.

[21]  M. Espié,et al.  Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Mina J. Bissell,et al.  The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.

[23]  Erin M. Olson,et al.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  R. Weil,et al.  Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. , 2013 .

[25]  Gene silencing of c-Met leads to brain metastasis inhibitory effects , 2013, Clinical & Experimental Metastasis.

[26]  Wei Yin,et al.  The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis , 2013, Science Translational Medicine.

[27]  R. Greil,et al.  AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. McLendon,et al.  Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.

[29]  Xianghua Luo,et al.  The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer , 2013, Journal of Neuro-Oncology.

[30]  R. Jandial,et al.  Co-evolution of breast-to-brain metastasis and neural progenitor cells , 2013, Clinical & Experimental Metastasis.

[31]  D. Kuban,et al.  Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Mo,et al.  miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. , 2013, Cancer research.

[33]  M. D. Wetzel,et al.  A Correction to the Research Article Titled: "The Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis" by L. Zhang, L. D. Ridgway, , 2013 .

[34]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[35]  M. Preusser,et al.  Breast cancer brain metastases responding to primary systemic therapy with T-DM1 , 2013, Journal of Neuro-Oncology.

[36]  A. Chambers,et al.  Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications , 2013, Journal of Molecular Medicine.

[37]  P. Steeg,et al.  The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model , 2012, BMC Cancer.

[38]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[39]  R. Jain,et al.  Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases , 2012, Proceedings of the National Academy of Sciences.

[40]  S. Iwase,et al.  Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial , 2012, OncoTargets and therapy.

[41]  P. Kubes,et al.  Immune surveillance in the central nervous system , 2012, Nature Neuroscience.

[42]  P. Lollini,et al.  Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor , 2012, PloS one.

[43]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[44]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Dickler,et al.  RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer , 2012 .

[46]  G. Hortobagyi,et al.  Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Steinberg,et al.  Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. , 2012, Cancer research.

[48]  J. Polli,et al.  Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer , 2011, Pharmaceutical Research.

[49]  H. Woo,et al.  Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis , 2011, Proceedings of the National Academy of Sciences.

[50]  P. Meltzer,et al.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain , 2011, Clinical & Experimental Metastasis.

[51]  C. Betsholtz,et al.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. , 2011, Developmental cell.

[52]  K. Aldape,et al.  Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. , 2011, Cancer research.

[53]  H. Rugo,et al.  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER , 2011, Clinical Cancer Research.

[54]  P. Steeg,et al.  Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer , 2011, Molecular Cancer Research.

[55]  R. Jain,et al.  The biology of brain metastases—translation to new therapies , 2011, Nature Reviews Clinical Oncology.

[56]  R. Arriagada,et al.  Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  L. Lampson.  Monoclonal antibodies in neuro-oncology , 2011, mAbs.

[59]  P. Gunaratne,et al.  MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. , 2011, Cancer research.

[60]  L. Collette,et al.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  G. Mills,et al.  Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. , 2010, Neoplasia.

[62]  S. Yano,et al.  [PI3K inhibitor]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.

[63]  Tracy T Batchelor,et al.  Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.

[64]  Dai Fukumura,et al.  Malignant cells facilitate lung metastasis by bringing their own soil , 2010, Proceedings of the National Academy of Sciences.

[65]  S. Steinberg,et al.  Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis , 2010, Clinical Cancer Research.

[66]  Berislav V. Zlokovic,et al.  Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging , 2010, Neuron.

[67]  R. Plummer,et al.  Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Stephen Fox,et al.  HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010, Breast Cancer Research.

[70]  B. Felding-Habermann,et al.  Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. , 2010, The American journal of pathology.

[71]  S. Inoue,et al.  Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models , 2010, PloS one.

[72]  M. Ono,et al.  Disruption of the blood brain barrier by brain metastases of triple‐negative and basal‐type breast cancer but not HER2/neu‐positive breast cancer , 2010, Cancer.

[73]  Jochen Herms,et al.  Real-time imaging reveals the single steps of brain metastasis formation , 2010, Nature Medicine.

[74]  P. Meltzer,et al.  Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks , 2009, Clinical Cancer Research.

[75]  P. Steeg,et al.  Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer , 2009, Pharmaceutical Research.

[76]  B. Felding-Habermann,et al.  Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.

[77]  K. Camphausen,et al.  Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts , 2009, Molecular Cancer Therapeutics.

[78]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[79]  D. Roberge,et al.  Prophylactic cranial irradiation in advanced breast cancer: a case for caution. , 2009, International Journal of Radiation Oncology, Biology, Physics.

[80]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer , 2009, Clinical Cancer Research.

[81]  R. Greil,et al.  Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER 2-Positive Breast Cancer , 2009 .

[82]  M. Monje,et al.  Complications of radiation and chemotherapy Radiation therapy Acute reactions Cerebral edema Headaches Nausea Encephalopathy Early – delayed reactions Encephalopathy Cognitive dysfunction Myelopathy Endocrine dysfunction Vasculopathy Late – delayed reactions Cognitive dysfunction Dementia Necrosis L , 2008 .

[83]  J. Ohlfest,et al.  Effective CpG Immunotherapy of Breast Carcinoma Prevents but Fails to Eradicate Established Brain Metastasis , 2008, Clinical Cancer Research.

[84]  S. Steinberg,et al.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.

[85]  A. Vortmeyer,et al.  Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization , 2008, Clinical & Experimental Metastasis.

[86]  V. Heinemann,et al.  Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. , 2008, The oncologist.

[87]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[89]  L. Crinò,et al.  Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. , 2007, The oncologist.

[90]  G. Steger,et al.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer , 2007, Journal of Neuro-Oncology.

[91]  E. Gerstner,et al.  Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  G. Stoica,et al.  MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2 , 2007, Clinical & Experimental Metastasis.

[93]  W. Löscher,et al.  The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses , 2007, Clinical Cancer Research.

[94]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[95]  D. Moody,et al.  Vascular Damage after Fractionated Whole-Brain Irradiation in Rats , 2005, Radiation research.

[96]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[97]  Suyun Huang,et al.  Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice , 2004, Clinical & Experimental Metastasis.

[98]  R. McLendon,et al.  Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[100]  R. Jain,et al.  Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[102]  Y. Olsson,et al.  Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells , 1995, Journal of the Neurological Sciences.

[103]  W. Lane,et al.  Chemotherapy induces regression of brain metastases in breast carcinoma , 1986, Cancer.